constipation after stopping tirzepatide and GLP-1 Medications: What You Need to Know Severe constipation is never OK

Results A PRISMA flowchart is presented in Figure 1

Cardiovascular risk : If you have established cardiovascular disease or high cardiovascular risk, your clinician may favour agents with proven cardiovascular benefits in outcome trials, such as semaglutide, liraglutide, or dulaglutide

HIMABERB is composed of 100% Berberine HCl with no carriers or excipients

The HRV kept dropping

Monitored interventions (dietary elimination protocols, gut repair, detox support, IV nutrient infusions when indicated, LDN or BHRT via NP) with objective lab follow-up

Who should avoid the combination There are some situations where the combination may not be recommended